compani lly-
still sweet solid result
invest summari ep beat maintain ow rate
month pt expect upward earn revis move share
higher driven sale growth margin expans pipelin
takeaway support posit thesi revenu grew
driven volum growth growth product includ trulic
taltz verzenio basaglar olumi jardianc cyramza emgal
repres revenu complet acquisit loxo
oncolog broaden scope oncolog portfolio precis
medicin first-in-class oral ret inhibitor grant
breakthrough therapi design fda three indic
initi potenti launch complet previous announc
disposit busi result recogn
gain elanco disposit fda grant prioriti
review sbla emgal prevent treatment episod
cluster headach adult olumi approv ad offer
dermatologist oral option given dupix inject ad
market could play similarli seen psoriasi suggest
larg potenti opportun olumi sever first-in-class
late-stag asset import readout next month includ
mirikizumab pegilodecakin tirzepatid ret-inhibitor emgal
track surpass aimovig nrx reimburs also improv
commerci claim reimburs exit
report adjust dilut ep factset
consensu higher estim updat ep
guidanc reflect disposit elanco anim
busi repres yoy ep growth factset consensu
revis model result lower
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
greater-than-expect brand and/or gener competit lilli key drugs/product
number lilli top-sel human pharmaceut product recent lost
lose next sever year signific patent protect and/or data protect
well key countri outsid certain signific product longer
effect exclus patent protect data protect non-biolog product
loss exclus whether expir consequ litig typic result
entri one gener competitor lead rapid sever declin
revenu especi histor outsid market penetr gener
follow loss exclus rapid pervas howev gener
market penetr increas mani market outsid includ japan europ
mani countri emerg market biolog humalog humulin erbitux
cyramza trulic taltz loss exclus may may result near-term entri
competitor version biosimilar due develop timelin manufactur challeng
and/or uncertainti regulatori pathway approv competitor version
setback lilli pipelin could headwind compani futur growth prospect
lilli compet larg number multi-national pharmaceut compani biotechnolog
compani gener pharmaceut compani compet success lilli must
continu deliv market innov cost-effect product meet import medic
lilli human pharmaceut busi subject increas govern price control
public privat restrict price reimburs access drug
could materi advers effect busi public privat payer take
increasingli aggress step control expenditur human pharmaceut
place restrict price reimburs patient access lilli medic
pressur could neg affect futur revenu net incom lilli expect
price reimburs access pressur govern privat payer insid
outsid becom sever
manufactur difficulti disrupt could lead product suppli problem
anim health manufactur complex highli regul
manufactur difficulti lilli facil contract facil failur refus
contract manufactur suppli contract quantiti could result product shortag
lead lost revenu difficulti disrupt could result qualiti regulatori
complianc problem natur disast mechan inform technolog system failur
inabl obtain sole-sourc raw intermedi materi addit given difficulti
predict sale new product long lead time necessari expans
regulatori qualif pharmaceut manufactur capac possibl lilli
could difficulti meet unanticip demand new product
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
bear case scenario base analysi estim likelihood stock worth
next month
exhibit bull bear base case scenario analysi
cantor fitzgerald research compani reportsbul casesal trulic jardianc taltz verzenio key drug exceed expectationspipelin advanc exceed expectationsstrateg accret scenario casesal trulic jardianc taltz verzenio key drug line expectationspipelin advanc line expectationsno scenario casesal trulic jardianc taltz verzenio key drug expectationspipelin advanc expectationsno scenario exhibit varianc analysi
amount chang yoyamount chang yoyvariancecommentstot driven volum growth key product trulic taltz verzenio basaglar gross oper non oper pre-tax tax rate driven time associ impact tax reform adjust net averag regular on-going share repurchas program adjust dilut cantor fitzgerald research compani reportsactualcantor exhibit catalyst event calendar
datedriverupcom galcanezumab approv episod cluster top-line readout crohn control bayer phase data phase studi june dulaglutid present detail rewind result ada scientif sessionsjun linagliptin present full phase carolina cv outcom data ada scientif sessionsjun premetrex patent litig altern salt form appeal cafc dr reddi abemaciclib phase trial ramucirumab merestinib data pivot phase trial biliari tract top-line readout clbp studi ramucirumab global regulatori submiss phase relay data egfr nsclc erlotinib combo august exclus europ japan septemb nordisk oral semaglutidefda decis treatment adult type oral phase full data top-line on-going ad phase baricitinib phase initi alopecia initi crohn pegyl phase renal cell antibodyphas readout identifi biomark key kinas inhibitorphas posit alloster modul pam phase readout parkinson diseas glucagonregulatori decis /eu top-line data congest heart failur chf exercis abil ixekizumab regulatori submiss radiograph axial spondyloarthr ixekizumab regulatori action radiograph axial ixekizumab regulatori submiss non-radiograph axial ixekizumab phase top-line data psoriasi head-to-head vs tremfya guselkumab ramucirumab detail phase relay data egfr nsclc readout medic ramucirumab regulatori action high afp hepatocellular cancer lisprodata present medic meet type type studi public scientif meet data releas psoriat outcom studybegin enrol empagliflozin regulatori submiss type empagliflozin approv type agonist present full titrat studi data help manag gi side effect medic approv acut migrainesourc cantor fitzgerald research compani report exhibit catalyst event calendar continu
datedriverupcom studi overcom avail baselin dulaglutid phase top-line data altern dose type phase emperial-preserv outcom trial chronic phase emperial-reduc outcom trial chronic abemaciclib keytrudaphas data hr breast cancer kra nsclc non-squam agonist initi phase studi agonist initi phase studi non-alcohol steatohepat ret inhibitor registr phase data nsclc thyroid pegyl pembrolizumab cypress nsclc top-line pegyl nivolumab io nave cypress nsclc top-line ret inhibitor submiss nsclc thyroid cancer end agonist initi surpass studi type diabetesend ceclor vancocin eddingpharm chinad nordisk oral semaglutidefda decis cv risk reduct adult type diabet pegyl folfoxphas sequoia pancreat cancer top-line baricitinib phase top-line data alopecia lispropotenti overal surviv os top-line data agonist initi surpass cvot event driven power cv dulaglutid label updat rewind phase emperor hf-preserv outcom trial chronic phase emperor hf-reduc outcom trial chronic phase empa-kidney outcom trial chronic kidney readout alzheim diseas readout dian readout solid tumorsearli readout cancer pain studi abemaciclib result phase adjuv studi hr breast cancer baricitinib phase top-line data system lupu antibodyphas readout alzheim top-line data ulcer agonist phase surpass data type diabet vs glargin establish pegyl insulin deliveri systempotenti outcom studymain studi premetrex eu loss premetrex japan loss control bayer submissionl agonist complet phase surpass program type diabetesmay premetrex patent expir loss pediatr exclus empagliflozin phase estimate primari complet date chronic kidney diseas control bayer potenti agonist potenti global studi overcom end data abemaciclib nce exclus readout aspirinu patent dulaglutid patent agonist data surpass cvot event driven power cv patent patent jentaduet patent ramucirumab patent ixekizumab patent abemaciclib patent baricitinib eu patent baricitinib patent ixekizumab eu loss baricitinib japan patent galcanezumab patent expirationsourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
exhibit incom statement analysi
exhibit margin analysi
exhibit quarterli sale analysi
exhibit annual sale analysi
pharmaceut product pharmaceut intern pharmaceut launch pipeline/newli launch product cantor fitzgerald research compani report cardio includ zalutia livalo endocrinolog includ acto humapen neuro includ amyvid symbyax onco includ gemzar portrazza pharma includ ceclor keflex licens fee incom jardianc revenu includ glyxambi synjardi trajenta revenu includ jentadueto biolog humalog humulin erbitux cyramza trulic taltz loss exclus may may result near-term entri competitor version biosimilar due develop timelin manufactur challeng and/or uncertaintiesin regulatori pathway approv competitor version year end decemb exhibit analysi
exhibit balanc sheet analysi
engag discoveri develop manufactur sale pharmaceut product compani sell product world-wide
follow therapeut area neurosci endocrinolog oncolog cardiovascular
